SCROLL DOWN

Better Therapy Brighter Outlook
LT3001

tPA is the only drug approved to treat stroke with serious side effects and unsatisfactory outcomes.

  • <3hr is eligible to receive tPA

  • Actual usage of tPA 3%~5%

  • High risk of hemorrhage

LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.

NEWS
Finance

2024.12.05

Media Report Clarification
Finance

2024.12.03

Media Report Clarification
Finance

2024.11.29

Lumosa Announces Details of Upcoming Institutional Investor Conference
Finance

2024.11.29

Lumosa and Center Lab to Hold Joint Investor Press Conference for Material Announcement on 24/11/29
Finance

2024.05.14

Center Lab Group Executive Takes Helm as New Lumosa Chairman to Drive Global Licensing of LT3001 Stroke Candidate
Finance

2023.12.05

Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024
Corporate

2023.09.26

Lumosa Partner, AMed Co., Informed the Receipt of Market Authorization from Brunei (BDMCA), for Naldebain, an Extended-Release Analgesic Injection
Corporate

2023.07.26

LT3001 Received Formulation Patent from USPTO
Corporate

2023.05.15

Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate

2023.04.19

First subject for LT3001 Phase 2 trial enrolled in China
Corporate

2023.03.07

Lumosa Therapeutics Announces an Out-License Agreement with Pakistan’s AJM Pharma for LT1001
Corporate

2023.02.10

Lumosa Attending the 2023 International Stroke Conference
Finance

2022.11.04

Lumosa will participate in the "Biotech Forum" sponsored by Masterlink Securities
Corporate

2022.11.01

Lumosa Exhibiting at CPhI Frankfurt 2022
Corporate

2022.09.23

Lumosa One of the Finalists for Clinical Advance of the Year Award in Scrip Awards 2022
Corporate

2022.01.11

Lumosa Receives U.S. FDA Fast Track Designation for Its LT3001, a Novel Drug for the Treatment of Acute Ischemic Stroke
Corporate

2021.12.29

Lumosa Receives Market Approval for Its Long-Acting Analgesic Injection from Thailand
Corporate

2021.12.24

Phase 2 IND for Lumosa's Novel Stroke Therapy Approved by Taiwan FDA
Corporate

2021.11.16

LT1001 Formulation Patent Granted by JPO
Corporate

2021.09.16

Lumosa Therapeutics Announces FDA Clearance of IND Application Its LT3001, a New Drug for the Treatment of Acute Ischemic Stroke, for Multi-dose Phase 2 Trial in Combination with Mechanical Thrombectomy
Corporate

2021.09.05

Lumosa CEO's Interview by Kevin Price on the Price of Business Show
Corporate

2021.08.03

Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke
Corporate

2021.06.23

Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea – Securing a Foot in Northeast Asia and Increase Global Licensing Value
Corporate

2021.06.16

Formulation Patent for LT1001, An Extended-Release Analgesic Injection, Granted by Chinese Patent Office
Corporate

2021.05.25

Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection
Corporate

2021.02.01

LT3001 Compound Patent Approved in Korea and Europe
Corporate

2020.12.17

Naldebain Approved by Singapore HSA
Corporate

2020.12.14

Lumosa to commence a multi-dose Phase 1 trial right after the single-dose Phase 2 to expand stroke treatment methodology
Corporate

2020.12.04

Enrollment Completed for 1st Phase 2 Trial for LT3001
Corporate

2020.09.14

LT3001 Received IND Approval from China's NMPA
Corporate

2020.08.10

Patent for Lumosa's Extended-Release Analgesic Granted by Taiwan IPO
Corporate

2020.03.02

The US FDA has granted the Orphan Drug Status to Lumosa's LT2003, an anti-tumor targeting fusion protein, for the treatment of pancreatic cancer

Learn More

Investors

Learn More